BioSpace News Archive

Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) in National Harbor, MD from November 6 – 10, 2019.

A new survey from Health Union finds that people with relapsing forms of multiple sclerosis (MS) who currently use a disease-modifying therapy (DMT) report positive relationships with their healthcare professionals (HCP) and interest in prescription therapies, while those who have never used a DMT prefer alternative therapies and have experienced a less straight-forward MS journey than their counterparts

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced duvelisib (COPIKTRATM) has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of T-Cell lymphoma.

Heron Therapeutics, Inc. announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

The U.S. Food and Drug Administration approved Descovy in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.

Data Powered by The Aural Analytics Speech Analytics Platform Technology Will be Presented at The 18th Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting

The Board of Directors of Zoetis Inc. has declared a fourth quarter 2019 dividend payable to holders of the company’s common stock of $0.164 per share.

CVS Health Corporation announced that its board of directors has approved a quarterly dividend of $0.50 per share on the corporation’s common stock.

Medicure Inc. is pleased to announce that it has reached a preferred pricing agreement with the AIDS Drug Assistance Program Crisis Task Force for ZYPITAMAGTM tablets.

Heron Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price of $17.50 per share.